 |
|
| |
|
|
| |
|
|
|
|
|
|
|
| |
Partnerships in Catalonia - Spain
|
|
|
|
|
|
|
|
Barcelona Biomedical Alliance
Barcelona Biomedical Alliance (BBA)
brings together the research programmes, infrastructures,
resources and more than 2500 researchers from the Institut
d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
Parc
Científic de Barcelona of the Universitat
de Barcelona and Parc
de Recerca Biomèdica de Barcelona. The Universitat
Autònoma de Barcelona (UAB) has joined this
initiative as a permanent guest member of its Board.
This alliance combines the efforts of institutions with
highly qualified personnel equipped with the last technological
advances. In this way, IDIBAPS is immersed in a project
of organisation of biomedical research in Barcelona
with the aim to turn Barcelona into an excellence centre
of Catalan and Spanish biomedical production. This initiative
has the institutional support of the Universities,
Research and Information Society Department of
the Generalitat
de Catalunya and the Spanish
Ministry of Science and Technology.
The main objectives of Barcelona Biomedical Alliance are:
To form an only catalogue of lines of research of
quality and excellence, by coordinating the research
programmes and the best actives of their institutions.
Thus, Alliance will have a joined framework within the
European sphere of research and the international scientific
community.
To organise a Consortium among the scientific and
technical services and the large infrastructures that
form it, with the aim to rationalize the resources at
their disposal. It also has the mission to strategically
manage the new technical needs of the research groups
of the Alliance.
To cooperate closely so as to create new opportunities
and better resources for the scientific entrepreneurs,
as to contribute to the establishment of a new culture
of relationships among the academic spheres and the
enterprise.
Download
speech by Dr. Jordi Camí,
Parc de Recerca Biomèdica de Barcelona's Director,
during the Alliance signature
|
|
| |
|
|
| |
| Catalan
Association of Research Institutions |
 |
The Catalan Association of Research Institutions (ACER, Associació Catalana d'Entitats de Recerca) joins together all the research centres promoted by the Generalitat de Catalunya. Its members are committed to support on the administration, management, transmission of the information, research and organisation of research and spreading activities. Furthermore, this initiative will constitute a permanent forum of scientific information for the society and will boost the private involvement through the patronage and participation of private sources in research. On the 12th March 2003, in the central office of the Fundació Catalana per a la Recerca, the agreement of constitution of the ACER was signed, involving the following 24 research centres:
|
|
| |
|
|
| |
International networks of cooperative research (www.idibaps.ub.edu/redes)
The high scientific
potential of IDIBAPS allows it to access the public
funds from a privileged position. Its important participation
in the recently created international networks of cooperative
research proves it. The Health
Ministry, , through the Fondo de Investigación Sanitaria
(FIS), has the aim to promote scientific research on
biomedicine with these networks, through the collaboration
among groups and research centres countrywide.
IDIBAPS participates in 12 networks of centres and in
25 networks of groups, and it leads five of them in
fields as diabetes, AIDS, hepathology and cardiovascular
disease. The networks of centres create bonds of collaboration
among different institutions remarkable in some field.
To join this initiative it is needed to have different
excellence groups devoted to the field in which every
network is focused. The groups approximate the researchers
of different groups that stand out in certain areas
of biomedicine.
The networks leaded by IDIBAPS are the following:
Networks of Centres:
- Nacional Research Network in Hepathology and Gastroenterology (RNIHG, Red Nacional de investigación de Hepatología y Gastroenterología).
Coordinated by Dr. Jaume Bosch, leader of the
Hepatic Haemodinamics and Portal Hypertension group
of IDIBAPS.
- Molecular determinants of metabolism and nutrition. New therapeutical strategies.
Coordinated by Dr. Ramon Gomis, leader of the Experimental Diabetes group of IDIBAPS and research director of Hospital Clínic de Barcelona.
Networks of Groups:
- Effects of the Mediterranean diet in primary prevention of the cardiovascular disease.
Coordinated by Dr. Ramon Estruch, member of the Secondary Lesions by Chronic Alcohol Consumption group of IDIBAPS.
- Network of research on AIDS (RIS, Red de investigación en SIDA).
Coordinated by Dr. Josep Maria Gatell, leader of the Infectious Diseases and AIDS group of IDIBAPS and leader of the Infectious Diseases Service of Hospital Clínic de Barcelona.
- Metabolic and molecular defects of diabetes mellitus and their complications. Gene and cell therapy.
Coordinated by Dr. Ramón Gomis, leader of the Experimental Diabetes group of IDIBAPS and research director of Hospital Clínic de Barcelona.
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
With long-term projects
financed by the AECI and in collaboration with numerous
institutions, IDIBAPS consolidates its recognition abroad.
From its creation, IDIBAPS has cultivated its international relations through scientific collaboration and contributions at conferences. Its researchers have received subsidies from the National
Institutes of Health and the European Commission, and have joined efforts with prestigious international institutions, such as Malaria
Vaccine Initiative , theYale University, el Karolinska
Institute, the
Leuven University, the Juvenil
Diabetes Research Foundation and the French
INSERM Hospitals. In this way, IDIBAPS has been consolidating its recognition abroad.
On the other hand, IDIBAPS'
International Epidemiology and Health Research Group
has been increasing its research and co-operation activity in international health problems since 1998. One of its more important projects is the development of the Manhiça Health Research Centre in Mozambique. It is a Hispano-Mozambican co-operation institution for development with training, research, and health care. Its funding comes mostly from the Agencia Española de Cooperación Internacional (AECI) of the Ministry of Foreign Affairs , and some of its research projects are supported by entities as important as BBVA Foundation or "La Caixa" Foundation.
Also a line of co-operation has been established between IDIBAPS and Morocco through the rehabilitation and start up of the maternity ward of the Hospital Español de Tetuán. This project, financed by the AECI, seeks to reduce the mortality rate among the women of this zone during childbirth.
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
|
|
|
|
|
| |
Partnerships with private industry |
|
|
|
|
|
|
|
IDIBAPS has qualities that can be very useful for developing medicines
IDIBAPS is the perfect framework for several of the crucial stages in the process of developing new medicines. The response to many problems and clinical unknowns can only be approached through the collaboration of the material and human resources of the pharmaceutical industry and of centres with the characteristics such as those of the Institut d'Investigacions Biomèdiques August Pi i Sunyer. Basic biomedical research and applied clinical research, together with quality specialised health care practice, are the qualities of IDIBAPS that can be of great usefulness for the development of medicines. With this in mind, IDIBAPS is a privileged interlocutor for the pharmaceutical industry, whether it is national capital (located fundamentally in Catalonia) or multinational. The evaluation, support and prevention unit has the necessary resources to efficiently manage the collaboration with the pharmaceutical industry in the design, the execution, the analysis, and the approval of clinical trials with medicines in phases I, II, III, and IV.
IDIBAPS maintains stable lines of collaboration with biomedicine and biotechnology companies. Every year, about 300 clinical tests with medicines or biomedical devices in various phases of development are evaluated, 75% of which are promoted by private companies.
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
|
